CVSIOTCPharmaceutical PreparationsFiscal year ends December 31

CV Sciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.01−0.00 (-21.13%)

Close on Oct 19, 2026

Market cap: $2.30M
P/E (TTM): –
Dividend yield: –

CV Sciences, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31
Revenue	14	16	16	16	20	24	54	48	21	11	12	10	2.15	0	–
Cost of Revenue	7.04	8.54	8.92	11	11	13	19	14	6.19	4.06	4.80	4.39	0.88	0	–
Gross Profit	6.75	7.17	7.09	5.55	8.62	11	35	34	14	7.00	6.73	5.80	1.27	0	–
Research & Development	0.12	0.12	0.15	0.31	1.19	2.94	5.88	1.89	0.72	1.16	1.32	1.00	0.52	0	–
Selling, General & Admin	7.62	9.24	9.75	12	26	31	46	22	16	13	17	–	–	0.04	0.09
General & Administrative	3.15	3.99	3.74	12	26	31	46	22	16	13	17	13	2.37	0.04	0.09
Advertising Expenses	0.10	0.50	1.10	1.20	1.30	1.30	2.50	0.90	0.38	0.31	0.19	–	–	–	–
Operating Expenses	–	–	–	12	27	34	52	24	19	20	19	14	2.89	0.04	0.09
Operating Income	-0.47	-2.19	3.36	-6.85	-18	-23	-17	10	-4.86	-13	-11	-8.55	-1.62	-0.04	–
Interest Expense	0.52	0.21	–	0.60	0.04	–	–	0.15	0.51	1.09	0.97	0.62	0.37	0.00	0.00
Income from Equity Investments	–	–	–	–	–	–	–	–	–	–	0	-0.04	-0.31	0	–
Other Non-Operating Income	-0.48	-0.21	-0.26	-1.54	–	–	–	-0.15	-0.52	-1.07	-1.02	7.24	-0.68	–	–
Asset Impairment Charges	0	0	0	1.23	5.03	0	0	0	0	2.75	0	0	0	–	–
Gain (Loss) on Investments	–	–	–	–	–	–	–	–	–	–	0	-0.04	-0.31	0	–
Gain (Loss) on Sale of Assets	–	–	0	-0.15	-0.03	-0.19	0	0	-0.01	-0.01	0	–	–	–	–
Pretax Income	-0.95	-2.40	3.10	-8.26	-16	-23	-17	10	-5.38	-14	-12	–	–	–	–
Income Tax Expense	0.01	-0.01	-0.01	-0.05	-0.09	-0.32	-0.62	0.09	-0.48	0	0	0	0	0	–
Income from Continuing Operations	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.04	-0.09
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	–	–	–	–	-12	-1.31	-2.30	-0.05	–
Net Income	-0.96	-2.39	3.10	-8.21	-16	-22	-17	10	-4.90	-14	-12	-1.31	-2.30	-0.05	-0.09
Net Income to Common	–	-2.39	3.10	-9.13	-16	–	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	-0.01	-0.01	0.02	-0.07	-0.14	-0.22	-0.17	0.11	-0.06	-0.27	-0.35	-0.04	-0.23	-0.01	-0.01
EPS (Diluted)(per share)	-0.01	-0.01	0.02	-0.07	-0.14	-0.22	-0.17	0.09	-0.06	-0.27	-0.35	–	-0.23	-0.01	-0.01
Shares Outstanding (Basic, Weighted)(shares)	184	176	154	138	108	100	98	92	80	53	35	32	9.88	7.00	6.97
Shares Outstanding (Diluted, Weighted)(shares)	184	176	154	138	108	100	98	114	80	53	35	32	9.88	7.00	6.97
EBITDA	-0.28	-1.86	3.60	-5.86	-17	-22	-17	11	-4.68	-12	-10	-7.62	-0.85	-0.04	–
Net Interest Income	–	–	–	-1.54	-0.14	-0.01	0.02	-0.15	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 49.1%
Operating margin: -7.6%
Net margin: -15.7%
Return on equity, FY2025: -58.7%

Financial strength

Current ratio: 0.99
Debt to equity: 0.01
Debt to assets: 0.3%
Cash to current liabilities: 5.4%

Valuation

P/E ratio: –
Price to sales: 0.18
Price to book: 1.46
Dividend yield: –